1. 1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine. (31st December 2020) Authors: Brar, Indira; Ruane, Peter; Ward, Douglas; Molina, Jean-michel; Mills, Anthony; Berhe, Mezgebe; Brinson, Cynthia; Rampogal, Moti; Benson, Paul; Henry, Keith; Huang, Hailin; Andreatta, Kristen; Martin, Hal Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S543 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis. (December 2014) Authors: Sulkowski, Mark; Kowdley, Kris; Ruane, Peter; Hawkins, Trevor; Elion, Richard; Workowski, Kimberly; Mills, Anthony; Subramanian, Mani; Ding, Xiao; Seyedkazemi, Star; Hyland, Robert H.; Yang, Jenny C.; Pang, Phillip S.; Mchutchison, John G.; Afdhal, Nezam; Wyles, David Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial. (4th December 2021) Authors: Ramgopal, Moti; Ruane, Peter; Shao, Yongwu; Ebrahimi, Ramin; Kintu, Alex; Carter, Christoph C; Das, Moupali; Baeten, Jared; Brinson, Cynthia; Shalit, Peter; Mounzer, Karam Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial. (4th December 2021) Authors: Ramgopal, Moti; Ruane, Peter; Shao, Yongwu; Ebrahimi, Ramin; Kintu, Alex; Carter, Christoph C; Das, Moupali; Baeten, Jared; Brinson, Cynthia; Shalit, Peter; Mounzer, Karam Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Antiretroviral switch studies do matter. Issue 10 (October 2018) Authors: Daar, Eric S; Ruane, Peter; DeJesus, Edwin; Stellbrink, Hans-Jürgen; Molina, Jean-Michel Journal: Lancet Issue: Volume 5:Issue 10(2018) Page Start: e546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Issue 2 (15th February 2021) Authors: Loomba, Rohit; Noureddin, Mazen; Kowdley, Kris V.; Kohli, Anita; Sheikh, Aasim; Neff, Guy; Bhandari, Bal Raj; Gunn, Nadege; Caldwell, Stephen H.; Goodman, Zachary; Wapinski, Ilan; Resnick, Murray; Beck, Andrew H.; Ding, Dora; Jia, Catherine; Chuang, Jen‐Chieh; Huss, Ryan S.; Chung, Chuhan; Subram... Journal: Hepatology Issue: Volume 73:Issue 2(2021) Page Start: 625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Early fusion events and invasive behaviour in trophoblast at sites of implantation in vitro. (September 2016) Authors: Ruane, Peter; Watts, Jessica; Berneau, Stephane; Kimber, Susan; Westwood, Melissa; Brison, Daniel; Aplin, John Journal: Placenta Issue: Volume 45(2016:Sep.) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Early fusion events and invasive behaviour in trophoblast at sites of implantation in vitro. (September 2016) Authors: Ruane, Peter; Watts, Jessica; Berneau, Stephane; Kimber, Susan; Westwood, Melissa; Brison, Daniel; Aplin, John Journal: Placenta Issue: Volume 45(2016:Sep.) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Issue 7 (July 2018) Authors: Daar, Eric S; DeJesus, Edwin; Ruane, Peter; Crofoot, Gordon; Oguchi, Godson; Creticos, Catherine; Rockstroh, Jürgen K; Molina, Jean-Michel; Koenig, Ellen; Liu, Ya-Pei; Custodio, Joseph; Andreatta, Kristen; Graham, Hiba; Cheng, Andrew; Martin, Hal; Quirk, Erin Journal: Lancet Issue: Volume 5:Issue 7(2018) Page Start: e347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Issue 4 (April 2016) Authors: Gallant, Joel E; Daar, Eric S; Raffi, François; Brinson, Cynthia; Ruane, Peter; DeJesus, Edwin; Johnson, Margaret; Clumeck, Nathan; Osiyemi, Olayemi; Ward, Doug; Morales-Ramirez, Javier; Yan, Mingjin; Abram, Michael E; Plummer, Andrew; Cheng, Andrew K; Rhee, Martin S Journal: Lancet Issue: Volume 3:Issue 4(2016) Page Start: e158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗